Kairos Pharma, LTD.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064
Mailing Address
2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064
Phone
818-404-5541
Fiscal Year End
1231
EIN
462993314
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | December 30, 2025 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
| 4 Insider stock transaction report | November 26, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Lead drug candidate ENV 105 showed 62% disease stabilization or shrinkage in Phase 2 trials.
- Secured a $3.2 million grant from the NIH, providing non-dilutive capital.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.